<DOC>
	<DOCNO>NCT00217256</DOCNO>
	<brief_summary>To demonstrate equivalency in-segment late lumen loss 8 month Endeavor Drug Eluting Coronary Stent System coat ABT-578 ( 10 micrograms/mm ) Cypher Sirolimus-Eluting Coronary Stent System treatment single de novo lesion native coronary artery 2.5-3.5 mm diameter .</brief_summary>
	<brief_title>The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial</brief_title>
	<detailed_description>The ENDEAVOR III Trial prospective , multi-center , single-blind , randomized trial enrol 436 patient 29 site US . The purpose trial demonstrate equivalency in-segment late lumen loss 8 month Endeavor stent Cypher stent treatment single de novo lesion native coronary artery 2.5-3.5 mm diameter . Patients randomize receive Endeavor stent Cypher Sirolimus-Eluting Coronary Stent System . Enrollment complete September 2004 .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . The patient least 18 year age . 2 . The patient must clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , positive functional study . 3 . The patient acceptable candidate percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery . 4 . Female patient childbearing potential must negative pregnancy test within seven ( 7 ) day procedure . 5 . The patient inform nature study agree provision provide write informed consent approve Institutional Review Board respective clinical site . 6 . The patient treat physician agree patient return treat research center , affiliated institution IRB jurisdiction , require postprocedure followup visit . A research staff member properly train Endeavor III protocol must conduct followup evaluation . 1 . A known hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , cobalt , nickel , chromium , molybdenum , sensitivity contrast medium , adequately premedicated . 2 . History allergic reaction significant sensitivity drug similar ABT578 ( rapamycin rapamycin analog ) . 3 . A platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , WBC &lt; 3,000 cells/mm³ . 4 . A creatinine level &gt; 2.0 mg/dL . 5 . Evidence acute myocardial infarction within 72 hour intend treatment ( define : Q wave nonQ wave myocardial infarction creatine kinase ( CK ) enzymes great equal 2X upper laboratory normal presence creatine kinase myocardialband isoenzyme ( CKMB ) elevate Institution 's upper limit normal ) . 6 . Any previous plan treatment vessel drug elute stent . 7 . Previous plan percutaneous coronary intervention vessel within 30 day pre post procedure . 8 . Previous stenting anywhere target vessel . 9 . During index procedure , target lesion require treatment device PTCA prior stent placement ( , limit , cut balloon , directional coronary atherectomy , excimer laser , rotational atherectomy , thrombectomy , etc. ) . 10 . History stroke transient ischemic attack within prior 6 month . 11 . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month . 12 . History bleed diathesis coagulopathy refuse blood transfusion . 13 . Concurrent medical condition life expectancy le 12 month . 14 . Any previous plan treatment target vessel antirestenotic therapy include , limited brachytherapy . 15 . Currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint ; require coronary angiography , intravascular ultrasound ( IVUS ) coronary artery imaging procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Restenosis</keyword>
</DOC>